On the contrary, a randomized phase I study reported no significant relationship between dose or serum testosterone levels and median time to progression (p = 0.072 and p = 0.14, respectively) among patients with low risk CRPC (histologically confirmed prostate cancer, PSA ≤ 3.0 ng/mL; rising PSA after surgical or chemical ADT) [110]. Here, KLK3 is linked to prostate carcinoma.